Omada Health Launches GLP-1 Flex Care to Address Employer Cost Concerns
Event summary
- Omada Health introduced GLP-1 Flex Care on March 5, 2026, a program allowing employers to support employee access to GLP-1 medications without covering direct medication costs.
- The program includes clinical evaluation, prescribing, and ongoing medical oversight, with employees purchasing medications independently through cash-pay channels.
- Omada claims its GLP-1 care track demonstrates higher medication persistence rates (67%) and greater average weight loss (18.4%) compared to published benchmarks.
- GLP-1 Flex Care will be available to employers later in 2026, expanding Omada's GLP-1 solution portfolio.
The big picture
Omada Health's GLP-1 Flex Care addresses a critical gap in employer-sponsored health benefits, where the high cost of GLP-1 medications has limited access despite growing employee demand. This move aligns with broader industry trends toward virtual-first care models and employer-driven health solutions. With over 150,000 members already supported on GLP-1s, Omada is positioning itself as a key player in the chronic disease management space, particularly for obesity and related conditions.
What we're watching
- Adoption Pace
- Whether employers will widely adopt GLP-1 Flex Care given its flexible, cost-controlled approach to GLP-1 medication support.
- Outcome Validation
- How Omada's real-world evidence on medication persistence and weight loss outcomes will hold up under broader implementation.
- Market Positioning
- The pace at which Omada can differentiate itself in the competitive landscape of employer-sponsored health benefits.
Related topics